世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

抗菌薬市場レポート：2024-2034


Antibacterial Drugs Market Report 2024-2034

レポート詳細 抗菌薬市場レポート 2024-2034年 ：本レポートは、業界とその基礎となるダイナミクスをより良く理解したい場合、新たな収益ポケットを目指している大手企業にとって貴重なものとなるで... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 図表数 言語
Visiongain
ヴィジョンゲイン社 		2024年1月16日 GBP5,150
部署ライセンス
ライセンス・価格情報
注文方法はこちら 		269 305 英語

※上記価格は部署ライセンス（Departmental licence）価格です。
その他の価格についてはデータリソースまでお問合せください。
日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


　

サマリー

レポート詳細

抗菌薬市場レポート 2024-2034年：本レポートは、業界とその基礎となるダイナミクスをより良く理解したい場合、新たな収益ポケットを目指している大手企業にとって貴重なものとなるでしょう。異業種への進出や新規地域での既存事業の拡大を目指す企業にとっても有用なレポートです。

研究開発の難しさ
抗菌薬の研究開発は、市場の魅力が限られているために影響を受けている。企業の参入を制限する主な要因は、慢性疾患治療薬に比べて短期間の抗菌薬治療では利益率が低いこと、耐性菌の出現による販売期間の制限、安価なジェネリック医薬品の入手可能性、抗菌薬の使用を制限するために必要なヘルスケア・スチュワードシップなどである。そのため、政府、学界、製薬業界による官民パートナーシップが数多く実施され、抗菌薬開発のための財政的・技術的支援が行われている。WHOによると、優先病原体に対して臨床開発中の新規抗生物質は、2017年の31種類に対し、2021年には27種類にとどまる。前臨床段階では過去3年間、製品数は一定している。臨床試験段階にある27種類の抗生物質のうち、WHOが定めるイノベーションの基準の少なくとも1つを満たすものは6種類に過ぎない。イノベーションの欠如は、限られた数の新しい抗生物質の有効性を弱めている。

抗生物質の不足
米国薬局方医薬品供給マップ分析によると、抗生物質の不足リスクが高まっており、抗菌薬耐性につながるサプライチェーンリスクがある。抗生物質不足の可能性は、他の医薬品と比較して42％高い。この分析は、米国で承認されたジェネリック医薬品の92％をカバーする40の外部データセットとUSP品質基準の使用に関する独自情報から導き出されたものである。抗菌薬不足はAMR問題への対応に影響する。調査によると、あらゆる種類の抗菌薬の中で、セファロスポリンは価格によって不足のリスクが高まっている。さらに、セファロスポリンに使用される原薬の40％が現在不足している。さらに、質の低い医薬品は、体内の微生物を治療量以下の医薬品にさらすことにより、抗菌薬耐性（AMR）を促進する。このため、患者は医薬品の有効成分（API）を十分に受け取ることができず、病原体が進化し、より多くの耐性株が出現する可能性がある。
同様に、欧州委員会、医薬品庁（HMA）、欧州医薬品庁（EMA）は2023年7月、呼吸器感染症の治療に不可欠な抗生物質（アモキシシリン、アモキシシリン／クラブラン酸、ペニシリン、アジスロマイシン、クラリスロマイシン、セフトリアキソン、セフォタキシム、ピペラシリン・タゾバクタムなど）の不足を防ぐための勧告を発表した。この勧告は、医薬品不足と安全性に関する執行運営グループ（MSSG）によって作成された。EMAと欧州保健緊急事態準備・対応局（HERA）は、販売承認管理者と協力し、呼吸器感染症に対する第一選択薬と第二選択薬の抗生物質が需要に見合うよう確保し、不足を回避する。

市場調査レポートを購入する前にすべき質問とは？
- 抗菌薬市場はどのように進化しているのか？
- 抗菌薬市場を牽引する要因と阻害要因は何か？
- 各抗菌薬サブマーケットセグメントは予測期間中にどのように成長し、2034年にはどれくらいの収益を占めるようになるのか？
- 2024年から2034年にかけて、各抗菌薬サブマーケットの市場シェアはどのように推移するのか？
- 2024年から2034年までの市場全体の主な牽引役は何か？
- 主要抗菌薬市場はマクロ経済の動きに大枠で追随するのか、それとも各国市場が他を凌駕するのか？
- 2034年までに各国市場のシェアはどのように変化し、2034年に市場をリードするのはどの地域か？
- 主要プレイヤーは誰で、予測期間中の見通しは？
- これらの大手企業の抗菌薬プロジェクトは？
- 2024年から2034年の間に、業界はどのように発展していくのか？現在および今後10年間に実施される抗菌薬プロジェクトにはどのような意味があるのか？
- 抗菌薬市場をさらに拡大するために、製品化の必要性は高まっているのか？
- 抗菌薬市場はどこへ向かっているのか？
- 新製品やサービスラインへの最適な投資方法とは？
- 企業を新たな成長軌道に乗せ、C-suiteに移行させるための重要な展望とは？

抗菌剤市場が現在、そして今後10年間でどのような影響を受けるかを知る必要がある：
- 269ページにわたる本レポートでは、113の表、192の図表を掲載しています。
- 本レポートでは、業界における主要な有利分野を取り上げているため、今すぐターゲットを絞ることができます。
- 本レポートには、世界、地域、国の売上と成長に関する詳細な分析が含まれています。
- 競合他社が成功した主なトレンド、変化、収益予測をハイライトしています。

本レポートは、抗菌薬市場が今後10年間でどのように発展するか、またCOVID-19の景気後退と好転の変動に合わせてどのように発展するかをお伝えします。この市場は、過去10年間のどの時点よりも今が重要である。

2034年までの予測やその他の分析から、商業的な展望が明らかになる
- 2034年までの収益予測に加え、最新の業績、成長率、市場シェアを提供します。
- ビジネスの展望と展開に関する独自の分析をご覧いただけます。
- 定性的分析（市場ダイナミクス、促進要因、機会、阻害要因、課題を含む）、コスト構造、抗菌薬価格上昇の影響、最近の動向をご覧いただけます。

本レポートには、COVID-19が業界と貴社にどのような影響を与えるかについてのデータ分析と貴重な洞察が含まれている。本レポートでは、COVID-19の4つの回収パターンとその影響、すなわち「V」、「L」、「W」、「U」について論じている。

レポート対象セグメント

薬剤クラス
- Β-ラクタム系
- キノロン系
- マクロライド系
- テトラサイクリン系
- アミノグリコシド系
- スルホンアミド系
- フェニコール
- その他

投与経路
- 経腸
- 非経口
- その他

流通チャネル
- 病院薬局
- 小売薬局
- オンライン薬局

世界市場全体とセグメント別の収益予測に加え、5つの地域と20の主要国市場の収益予測も掲載しています：

北米
- アメリカ
- カナダ

欧州
- ドイツ
- 英国
- フランス
- イタリア
- スペイン
- その他の欧州

アジア太平洋
- 中国
- 日本
- インド
- オーストラリア
- 韓国
- その他のアジア太平洋地域

ラテンアメリカ
- ブラジル
- メキシコ
- その他のラテンアメリカ

MEA
- GCC
- 南アフリカ
- その他のMEA

また、抗菌薬市場の2024年から2034年にかけての主要企業のプロファイルも掲載している。

報告書に掲載されている主要企業
・ AbbVie Inc.
・ AstraZeneca
・ Bayer AG
・ Bristol-Myers Squibb Company
・ GlaxoSmithKline plc
・ Johnson ＆ Johnson
・ Merck ＆ Co., Inc.
・ Novartis AG
・ Pfizer Inc.
・ Sanofi

2024年から2034年までの抗菌薬市場全体の世界売上高（金額ベース）は、2024年に391億7,870万米ドルを突破する。2034年まで力強い収益成長を予測。当研究所では、最も大きな可能性を秘めた組織を特定しています。彼らの能力、進歩、商業的展望を発見し、一歩先を行くお手伝いをします。

抗菌剤市場、2024-2034年レポートはどのようにお役に立ちますか？
要約すると、260ページに及ぶ本レポートは、以下のような知識を提供する：

- 抗菌薬市場、2024年から2034年までの収益予測 世界および地域レベルでの薬剤クラス、投与経路、流通経路ごとの予測を掲載 - 業界の将来性を発見し、投資と収益に最も有利な場所を見つけます。

- 5つの地域と20の主要国市場の2034年までの収益予測 - 北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、MEAの抗菌薬市場の2024年から2034年までの市場予測をご覧ください。また、米国、カナダ、メキシコ、ブラジル、ドイツ、フランス、英国、イタリア、中国、インド、日本、オーストラリアなど著名な経済圏の市場も予測しています。

- 2024年から2034年までの抗菌薬市場に関わる主要企業10社の企業プロファイルを含む、既存企業および市場参入を目指す企業の展望。

独自の予測による定量的・定性的分析をご覧ください。私たちのレポートだけに含まれる情報を入手し、貴重なビジネスインテリジェンスで情報を得ることができます。

他にはない情報
私たちの新しいレポートがあれば、知識に遅れをとったり、チャンスを逃したりする可能性が低くなります。Visiongainの調査レポートが貴社の調査、分析、意思決定にどのように役立つかをご覧ください。Visiongainの調査は、抗菌薬市場、2024年から2034年、市場をリードする企業の商業分析を必要とするすべての人のためのものです。データ、トレンド、予測をご覧いただけます。



ページTOPに戻る


目次

1.レポート概要
1.1 研究の目的
1.2 抗菌薬市場の紹介
1.3 本レポートの内容
1.4 本レポートを読むべき理由
1.5 本分析レポートが回答する主な質問は以下の通り：
1.6 本レポートは誰のためのものか？
1.7 方法論
1.7.1 市場の定義
1.7.2 市場評価・予測手法
1.7.3 データの検証
1.8 よくある質問（FAQ）
1.9 関連レポート
1.10 Visiongainについて

2 エグゼクティブ・サマリー
2.1 地理的スナップショット抗菌薬の世界市場
2.2 薬剤クラス別セグメント市場魅力度指数
2.3 投与経路セグメント市場魅力度指数市場魅力度指数
2.4 流通チャネルセグメント市場魅力度指数

3 市場概要
3.1 主要な調査結果
3.2 市場ダイナミクス
3.2.1 市場促進要因
3.2.2 市場抑制要因
3.2.3 市場機会
3.2.4 課題
3.3 COVID-19の影響分析
3.4 ポーターのファイブフォース分析
3.4.1 供給者パワー
3.4.2 バイヤーパワー
3.4.3 競争ライバル
3.4.4 代替品による脅威
3.4.5 新規参入の脅威

4 世界の抗菌薬市場分析：薬剤クラス別
4.1 主要な調査結果
4.2 薬剤クラス別の成長展望
4.3 薬剤クラス別抗菌薬の世界市場規模推定と予測
4.4 Β-ラクタム系抗菌薬
4.4.1 Β-ラクタム薬の地域別市場予測、2024年〜2034年（US$ Mn）
4.4.2 Β-ラクタム薬の地域別市場シェア、2024-2034年(%)
4.5 キノロン系抗菌薬
4.5.1 キノロン系抗菌薬の地域別市場予測、2024-2034 (US$ Mn)
4.5.2 キノロン系抗菌薬の地域別市場シェア、2024-2034年 (%)
4.6 マクロライド
4.6.1 2024-2034年のマクロライド系抗菌薬地域別市場予測 (US$ Mn)
4.6.2 マクロライドの地域別市場シェア、2024-2034年(%)
4.7 テトラサイクリン
4.7.1 テトラサイクリンの地域別市場予測、2024-2034 (US$ Mn)
4.7.2 テトラサイクリンの地域別市場シェア、2024-2034年 (%)
4.8 アミノグリコシド
4.8.1 アミノグリコシド系抗生物質の地域別市場予測、2024-2034 (US$ Mn)
4.9 スルホンアミド
4.9.1 スルホンアミドの地域別市場予測、2024-2034 (US$ Mn)
4.9.2 スルホンアミドの地域別市場シェア、2024-2034年 (%)
4.10 フェニコール類
4.10.1 フェニコールの地域別市場予測、2024-2034 (US$ Mn)
4.10.2 フェニコールの地域別市場シェア、2024-2034年 (%)
4.11 その他
4.11.1 その他の地域別市場予測、2024-2034 (US$ Mn)
4.11.2 その他の地域別市場シェア、2024-2034年 (%)

5 抗菌薬の世界市場：投与経路別分析
5.1 主要な調査結果
5.2 投与経路別セグメントの成長展望
5.3 投与経路別抗菌薬の世界市場規模推定と予測
5.4 2024年と2034年の投与経路別抗菌薬世界市場シェア
5.5 経腸
5.5.1 経腸薬の地域別市場予測、2024年-2034年 (US$ Mn)
5.5.2 経腸薬地域別市場シェア、2024年-2034年(%)
5.6 非経口剤
5.6.1 非経口剤の地域別市場予測、2024-2034年 (US$ Mn)
5.6.2 地域別非経口薬市場シェア、2024-2034年(%)
5.7 その他の地域
5.7.1 その他のRoA地域別市場予測、2024-2034 (US$ Mn)
5.7.2 その他のRoA地域別市場シェア、2024-2034年(%)

6 抗菌薬の世界市場分析：流通チャネル別
6.1 主要調査結果
6.2 流通チャネル別セグメント成長展望
6.3 流通チャネル別抗菌薬の世界市場規模推定と予測
6.4 抗菌薬の世界市場流通チャネル別シェア、2023年・2033年
6.5 病院薬局
6.5.1 病院内薬局の地域別市場予測、2024年‐2034年 (US$ Mn)
6.5.2 病院薬局の地域別市場シェア、2024年‐2034年(%)
6.6 小売薬局
6.6.1 小売薬局の地域別市場予測、2024-2034年（US$ Mn）
6.6.2 小売薬局の地域別市場シェア、2024-2034年(%)
6.7 オンライン薬局
6.7.1 オンライン薬局の地域別市場予測、2024-2034年（US$ Mn）
6.7.2 オンライン薬局の地域別市場シェア、2024-2034年 (%)

7 世界の抗菌薬市場分析：地域別
7.1 主要な調査結果
7.2 地域別市場規模の推定と予測

8 北米抗菌薬市場分析
8.1 主要な調査結果
8.2 北米の抗菌薬市場魅力度指数
8.3 北米の抗菌薬国別市場、2024年、2029年、2034年（US$ Mn）
8.4 北米の抗菌薬市場規模推定と予測：国別
8.5 北米の抗菌薬市場規模推定と予測：薬剤クラス別
8.6 北米の抗菌薬市場規模推定と予測：投与経路別
8.7 北米の抗菌薬市場規模推定と予測：流通経路別
8.8 米国
8.8.1 米国の抗菌薬市場：薬効分類別
8.9 カナダ
8.9.1 カナダの抗菌薬市場：薬効分類別

9 欧州の抗菌薬市場分析
9.1 主要な調査結果
9.2 欧州抗菌薬市場魅力度指数
9.3 欧州の抗菌薬国別市場、2024年、2029年、2034年（US$ Mn）
9.4 欧州の抗菌薬市場規模推定と予測：国別
9.5 欧州の抗菌薬市場規模推定と予測：薬剤クラス別
9.6 欧州の抗菌薬市場規模推定と予測：投与経路別
9.7 欧州の抗菌薬市場規模推定と予測：流通経路別
9.8 ドイツ
9.8.1 ドイツの抗菌薬市場：薬剤クラス別
9.9 イギリス
9.9.1 イギリスの抗菌薬市場：薬剤クラス別
9.10 フランス
9.10.1 フランスの抗菌薬市場：薬剤クラス別
9.11 イタリア
9.11.1 イタリアの抗菌薬市場：薬剤クラス別
9.12 スペイン
9.12.1 スペインの抗菌薬市場：薬剤クラス別
9.13 その他の地域
9.13.1 その他の欧州地域の薬剤クラス別抗菌薬市場

10 アジア太平洋地域の抗菌薬市場分析
10.1 主要な調査結果
10.2 アジア太平洋地域の抗菌薬市場魅力度指数
10.3 アジア太平洋地域の抗菌薬国別市場、2024年、2029年、2034年（US$ Mn）
10.4 アジア太平洋地域の抗菌薬市場規模推定と予測：国別
10.5 アジア太平洋地域の抗菌薬市場規模推定と予測：薬剤クラス別
10.6 アジア太平洋地域の抗菌薬市場規模推定と予測：投与経路別
10.7 アジア太平洋地域の抗菌薬市場規模推定と予測：流通経路別
10.8 日本
10.8.1 日本の抗菌薬市場：薬剤クラス別
10.9 中国
10.9.1 中国の抗菌薬市場：薬剤クラス別
10.10 インド
10.10.1 インドの抗菌薬市場：薬剤クラス別
10.11 韓国
10.11.1 韓国の抗菌薬市場：薬剤クラス別
10.12 オーストラリア
10.12.1 オーストラリアの抗菌薬市場：薬剤クラス別
10.13 その他の地域
10.13.1 その他のAPAC地域の薬剤クラス別抗菌薬市場

11 ラテンアメリカの抗菌薬市場分析
11.1 主要な調査結果
11.2 ラテンアメリカ抗菌薬市場魅力度指数
11.3 ラテンアメリカの抗菌薬国別市場、2024年、2029年、2034年 (US$ Mn)
11.4 ラテンアメリカの抗菌薬国別市場規模推定と予測
11.5 ラテンアメリカの抗菌薬市場規模推定と予測：薬効クラス別
11.6 ラテンアメリカの抗菌薬市場規模推定と予測：投与経路別
11.7 ラテンアメリカの抗菌薬市場規模推定と予測：流通経路別
11.8 ブラジル
11.8.1 ブラジルの抗菌薬市場：薬剤クラス別
11.9 メキシコ
11.9.1 メキシコの抗菌薬市場：薬剤クラス別
11.10 その他のラテンアメリカ地域
11.10.1 その他のラテンアメリカの薬剤クラス別抗菌薬市場

12 MEAの抗菌薬市場分析
12.1 主要な調査結果
12.2 MEA抗菌薬市場魅力度指数
12.3 MEAの抗菌薬国別市場、2024年、2029年、2034年（US$ Mn）
12.4 MEA抗菌薬の市場規模推定と予測：国別
12.5 MEAの抗菌薬市場規模推定と予測：薬剤クラス別
12.6 MEAの抗菌薬市場規模推定と予測：投与経路別
12.7 MEA抗菌薬の市場規模推定と予測：流通経路別
12.8 南アフリカ
12.8.1 南アフリカの抗菌薬市場：薬剤クラス別
12.9 GCC
12.9.1 GCCの抗菌薬市場：薬剤クラス別
12.10 その他のMEA
12.10.1 その他のMEA地域の薬効分類別抗菌薬市場

13 競争環境
13.1 企業ランキング分析
13.2 主要事業戦略分析

14 主要企業のプロファイル
14.1 Pfizer
14.1.1 会社概要
14.1.2 会社概要
14.1.3 財務分析
14.1.4 製品ベンチマーク
14.1.5 戦略的展望
14.2 Merck
14.2.1 会社概要
14.2.2 会社概要
14.2.3 財務分析
14.2.4 製品ベンチマーク
14.2.5 戦略的展望
14.3 GSK
14.3.1 会社概要
14.3.2 会社概要
14.3.3 財務分析
14.3.4 製品ベンチマーク
14.3.5 戦略的展望
14.4 AbbVie
14.4.1 会社概要
14.4.2 会社概要
14.4.3 財務分析
14.4.4 製品ベンチマーク
14.4.5 戦略的展望
14.5 Bayer Pharmaceuticals
14.5.1 会社概要
14.5.2 会社概要
14.5.3 財務分析
14.5.4 製品ベンチマーク
14.5.5 戦略的展望
14.6 Janssen Pharma (subsidiary of Johnson and Johnson)
14.6.1 会社概要
14.6.2 会社概要
14.6.3 財務分析
14.6.4 製品ベンチマーク
14.6.5 戦略的展望
14.7 AstraZeneca
14.7.1 会社概要
14.7.2 会社概要
14.7.3 財務分析
14.7.4 製品ベンチマーク
14.7.5 戦略的展望
14.8 Novartis
14.8.1 会社概要
14.8.2 会社概要
14.8.3 財務分析
14.8.4 製品ベンチマーク
14.8.5 戦略的展望
14.9 Bristol-Myers Squibb Company
14.9.1 会社概要
14.9.2 会社概要
14.9.3 財務分析
14.9.4 製品ベンチマーク
14.9.5 戦略的展望
14.10 Sanofi
14.10.1 会社概要
14.10.2 会社概要
14.10.3 財務分析
14.10.4 製品ベンチマーク
14.10.5 戦略的展望

15 結論と提言
15.1 報告書の最終所見
15.2 市場プレーヤーへの提言

ページTOPに戻る



図表リスト

表の一覧
Table 1 Global Antibacterial drugs Market Snapshot, 2024 & 2034 (US$ million, CAGR %)
Table 2 Antibacterial drugs Market, By Region, 2022-2034 (USD Mn, AGR %, CAGR %) (V-shaped Recovery)
Table 3 Gynecology Drugs Market, By Region, 2024-2034 (US$ Mn, AGR %, CAGR %) (U-shaped Recovery)
Table 4 Antibacterial drugs Market, By Region, 2024-2034 (US$ Mn, AGR %, CAGR %) (W-shaped Recovery)
Table 5 Antibacterial drugs Market, By Region, 2022-2034 (US$ Mn, AGR %, CAGR %) (L-shaped Recovery)
Table 6 Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 7 Examples of Beta-Lactam treatments
Table 8 β-lactams Market, by Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 9 Quinolones Market, by Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 10 Macrolides Market, by Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 11 Tetracyclines Market, by Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 12 Aminoglycosides Market, by Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 13 Sulfonamides Market, by Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 14 Phenicols Market, by Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 15 Others Market, by Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 16 Route of Administration Market, By Type 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 17 Examples of Enteral route drugs
Table 18 Enteral Market, by Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 19 Parenteral Market, by Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 20 Other Market, by Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 21 Antibacterial drugs Distribution Channel Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 22 Hospital Pharmacies Market, by Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 23 Retail Pharmacies Market, by Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 24 Online Pharmacies Market, by Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 25 Antibacterial drugs Market, By Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 26 North America Antibacterial drugs Market, By Country, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 27 North America Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 28 North America Route of administration Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 29 North America Distribution Channel Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 30 US Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 31 US Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 32 Canada Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 33 Canada Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 34 Europe Antibacterial drugs Market, By Country, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 35 Europe Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 36 Europe Route of administration Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 37 Europe Distribution Channel Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 38 Germany Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 39 Germany Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 40 UK Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 41 UK Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 42 France Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 43 France Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 44 Italy Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 45 Italy Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 46 Spain Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 47 Spain Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 48 Rest of Europe Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 49 Rest of Europe Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 50 Asia Pacific Antibacterial drugs Market, By Country, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 51 Asia Pacific Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 52 Asia-Pacific Route of Administration Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 53 Asia-Pacific Distribution Channel Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 54 Japan Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 55 Japan Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 56 China Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 57 China Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 58 India Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 59 India Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 60 South Korea Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 61 South Korea Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 62 Australia Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 63 Australia Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 64 Rest of Asia Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 65 Rest of Asia Pacific Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 66 Latin America Antibacterial drugs Market, By Country, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 67 Latin America Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 68 Latin America Route of Administration Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 69 Latin America Distribution Channel Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 70 Brazil Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 71 Brazil Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 72 Mexico Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 73 Mexico Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 74 Rest of Latin America Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 75 Rest of LATAM Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 76 MEA Antibacterial drugs Market, By Country, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 77 MEA Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 78 MEA Route of Administration Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 79 MEA Distribution Channel Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 80 South Africa Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 81 South Africa Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 82 GCC Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 83 GCC Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 84 Rest of MEA Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 85 Rest of MEA Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 86 Key Business Strategies Adopted by Key Players in Global Antibacterial drugs Market Details
Table 87 Pfizer: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 88 Pfizer: Product Benchmarking
Table 89 Pfizer Inc: Company Recent Developments
Table 90 Merck: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 91 Merck: Product Benchmarking
Table 92 Merck: Company Recent Developments
Table 93 GSK: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 94 GSK: Product Benchmarking
Table 95 GlaxoSmithKline: Company Recent Developments
Table 96 AbbVie: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website)
Table 97 AbbVie: Product Benchmarking
Table 98 AbbVie Inc: Company Recent Developments
Table 99 Bayer Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 100 Bayer Pharmaceuticals: Product Benchmarking
Table 101 Bayer Pharmaceuticals: Company Recent Developments
Table 102 Janssen Pharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 103 Janssen Pharma: Product Benchmarking
Table 104 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 105 AstraZeneca: Product Benchmarking
Table 106 AstraZeneca: Strategic Outlook
Table 107 Novartis: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 108 Novartis: Product Benchmarking
Table 109 AstraZeneca: Strategic Outlook
Table 110 BMS: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 111 BMS: Product Benchmarking
Table 112 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 113 Sanofi: Product Benchmarking
 
図の一覧
Figure 1 Global Antibacterial drugs Market Segmentation
Figure 2 Global Antibacterial drugs Market Forecast by Region: Market Attractiveness Index
Figure 3 Global Antibacterial drugs Market by Drug Class: Market Attractiveness Index
Figure 4 Global Antibacterial drugs Market by Route of Administration: Market Attractiveness Index
Figure 5 Global Antibacterial drugs Market by Distribution Channel: Market Attractiveness Index
Figure 6 Global Antibacterial drugs Market: Market Dynamics
Figure 7 Global Antibacterial drugs Market by Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%)): “V” Shaped Recovery
Figure 8 Global Antibacterial drugs Market by Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%)): “U” Shaped Recovery
Figure 9 Global Antibacterial drugs Market by Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%)): “W” Shaped Recovery
Figure 10 Global Antibacterial drugs Market by Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%)): “L” Shaped Recovery
Figure 11 Global Antibacterial drugs Market: Porter’s Five Forces Analysis
Figure 12 Global Antibacterial drugs Market Forecast by Drug Class 2023 (Revenue, CAGR%)
Figure 13 Global Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 14 Global Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 15 Β-lactams Market Forecast by Region, 2024-2034 (US$ million)
Figure 16 Β-lactams Market Share Forecast by Region, 2024-2034 (%)
Figure 17 Quinolones Market Forecast by Region, 2024-2034 (US$ million)
Figure 18 Quinolones Market Share Forecast by Region, 2024-2034 (%)
Figure 19 Macrolides Market Forecast by Region, 2024-2034 (US$ million)
Figure 20 Macrolides Market Share Forecast by Region, 2024-2034 (%)
Figure 21 Tetracycline Market Forecast by Region, 2024-2034 (US$ million)
Figure 22 Tetracyclines Market Share Forecast by Region, 2024-2034 (%)
Figure 23 Aminoglycosides Market Forecast by Region, 2024-2034 (US$ million)
Figure 24 Sulfonamides Market Forecast by Region, 2024-2034 (US$ million)
Figure 25 Sulfonamides Market Share Forecast by Region, 2024-2034 (%)
Figure 26 Phenicols Market Forecast by Region, 2024-2034 (US$ million)
Figure 27 Phenicols Market Share Forecast by Region, 2024-2034 (%)
Figure 28 Other Disease Market Forecast by Region, 2024-2034 (US$ million)
Figure 29 Other Market Share Forecast by Region, 2024-2034 (%)
Figure 30 Global Antibacterial drugs Market Forecast by Route of Administration 2023 (Revenue, CAGR%)
Figure 31 Global Antibacterial drugs Market Forecast by Route of Administration, 2024-2034 (US$ million, AGR %)
Figure 32 Global Antibacterial drugs Market Share Forecast by Route of Administration, 2024, 2029, 2034 (%)
Figure 33 Enteral Market Forecast by Region, 2024-2034 (US$ million)
Figure 34 Enteral Market Share Forecast by Region, 2024-2034 (%)
Figure 35 Parenteral Market Forecast by Region, 2024-2034 (US$ million)
Figure 36 Parenteral Market Share Forecast by Region, 2024-2034 (%)
Figure 37 Other Market Forecast by Region, 2024-2034 (US$ million)
Figure 38 Other Market Share Forecast by Region, 2024-2034 (%)
Figure 39 Global Antibacterial drugs Market Forecast by Distribution Channel 2023 (Revenue, CAGR%)
Figure 40 Global Antibacterial drugs Market Forecast by Distribution Channel, 2024-2034 (US$ million, AGR %)
Figure 41 Global Antibacterial drugs Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
Figure 42 Hospital Pharmacies Market Forecast by Region, 2024-2034 (US$ million)
Figure 43 Hospital Pharmacies Market Share Forecast by Region, 2024-2034 (%)
Figure 44 Retail Pharmacies Market Forecast by Region, 2024-2034 (US$ million)
Figure 45 Retail Pharmacies Market Share Forecast by Region, 2024-2034 (%)
Figure 46 Online Pharmacies Market Forecast by Region, 2024-2034 (US$ million)
Figure 47 Online Pharmacies Market Share Forecast by Region, 2024-2034 (%)
Figure 48 Global Antibacterial drugs Market Forecast by Region 2024, 2029, 2034 (Revenue)
Figure 49 Global Antibacterial drugs Market Share Forecast by Region 2024, 2029, 2034 (%)
Figure 50 Global Antibacterial drugs Market by Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Figure 51 North America Antibacterial drugs Market Attractiveness Index, 2023
Figure 52 North America Antibacterial drugs Market by Region, 2024, 2029 & 2034 (US$ million)
Figure 53 North America Antibacterial drugs Market Forecast by Country, 2024-2034 (US$ million, AGR %)
Figure 54 North America Antibacterial drugs Market Share Forecast by Country, 2024, 2029, 2034(%)
Figure 55 North America Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 56 North America Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 57 North America Antibacterial drugs Market Forecast by Route of Administration, 2024-2034 (US$ million, AGR %)
Figure 58 North America Antibacterial drugs Market Share Forecast by Route of Administration, 2024, 2029, 2034 (%)
Figure 59 North America Antibacterial drugs Market Forecast by Distribution Channel, 2024-2034 (US$ million, AGR %)
Figure 60 North America Antibacterial drugs Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
Figure 61 U.S. Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 62 U.S. Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 63 U.S. Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 64 Canada Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 65 Canada Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 66 Canada Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 67 Europe Antibacterial drugs Market Attractiveness Index, 2023
Figure 68 Europe Antibacterial drugs Market by Region, 2024, 2029 & 2034 (US$ million)
Figure 69 Europe Antibacterial drugs Market Forecast by Country, 2024-2034 (US$ million, AGR %)
Figure 70 Europe Antibacterial drugs Market Share Forecast by Country, 2024, 2029, 2034 (%)
Figure 71 Europe Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 72 Europe Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 73 Europe Antibacterial drugs Market Forecast by Route of Administration, 2024-2034 (US$ million, AGR %)
Figure 74 Europe Antibacterial drugs Market Share Forecast by Route of Administration, 2024, 2029, 2034 (%)
Figure 75 Europe Antibacterial drugs Market Forecast by Distribution Channel, 2024-2034 (US$ million, AGR %)
Figure 76 Europe Antibacterial drugs Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
Figure 77 Germany Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 78 Germany Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 79 Germany Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 80 UK Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 81 U.K. Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 82 U.K. Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 83 France Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 84 France Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 85 France Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 86 Italy Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 87 Italy Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 88 Italy Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 89 Spain Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 90 Spain Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 91 Spain Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 92 Rest of Europe Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 93 Rest of Europe Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 94 Rest of Europe Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 95 Asia Pacific Antibacterial drugs Market Attractiveness Index, 2023
Figure 96 Asia Pacific Antibacterial drugs Market by Region, 2024, 2029 & 2034 (US$ million)
Figure 97 Asia Pacific Antibacterial drugs Market Forecast by Country, 2024-2034 (US$ million, AGR %)
Figure 98 Asia Pacific Antibacterial drugs Market Share Forecast by Country, 2024, 2029, 2034 (%)
Figure 99 Asia Pacific Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 100 Asia Pacific Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 101 Asia-Pacific Antibacterial drugs Market Forecast by Route of Administration, 2024-2034 (US$ million, AGR %)
Figure 102 Asia-Pacific Antibacterial drugs Market Share Forecast by Route of Administration, 2024, 2029, 2034 (%)
Figure 103 Asia Pacific Antibacterial drugs Market Forecast by Distribution Channel, 2024-2034 (US$ million, AGR %)
Figure 104 Asia Pacific Antibacterial drugs Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
Figure 105 Japan Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 106 Japan Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 107 Japan Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 108 China Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 109 China Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 110 China Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 111 India Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 112 India Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 113 India Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 114 South Korea Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 115 South Korea Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 116 South Korea Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 117 Australia Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 118 Australia Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 119 Australia Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 120 Rest of Asia Pacific Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 121 Rest of APAC Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 122 Rest of APAC Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 123 Latin America Antibacterial drugs Market Attractiveness Index, 2023
Figure 124 Latin America Antibacterial drugs Market by Region, 2024, 2029 & 2034 (US$ million)
Figure 125 Latin America Antibacterial drugs Market Forecast by Country, 2024-2034 (US$ million, AGR %)
Figure 126 Latin America Antibacterial drugs Market Share Forecast by Country, 2024, 2029, 2034 (%)
Figure 127 Latin America Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 128 Latin America Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 129 Latin America Antibacterial drugs Market Forecast by Route of Administration, 2024-2034 (US$ million, AGR %)
Figure 130 Latin America Antibacterial drugs Market Share Forecast by Route of Administration, 2024, 2029, 2034 (%)
Figure 131 Latin America Antibacterial drugs Market Forecast by Distribution Channel, 2024-2034 (US$ million, AGR %)
Figure 132 Latin America Antibacterial drugs Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
Figure 133 Brazil Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 134 Brazil Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 135 Brazil Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 136 Mexico Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 137 Mexico Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 138 Mexico Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 139 Rest of LATAM Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 140 Rest of LATAM Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 141 Rest of LATAM Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 142 MEA Antibacterial drugs Market Attractiveness Index, 2023
Figure 143 MEA Antibacterial drugs Market by Region, 2024, 2029 & 2034 (US$ million)
Figure 144 MEA Antibacterial drugs Market Forecast by Country, 2024-2034 (US$ million, AGR %)
Figure 145 MEA Antibacterial drugs Market Share Forecast by Country, 2024, 2029, 2034 (%)
Figure 146 MEA Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 147 MEA Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 148 MEA Antibacterial drugs Market Forecast by Route of Administration, 2024-2034 (US$ million, AGR %)
Figure 149 MEA Antibacterial drugs Market Share Forecast by Route of Administration, 2024, 2029, 2034 (%)
Figure 150 MEA Antibacterial drugs Market Forecast by Distribution Channel, 2024-2034 (US$ million, AGR %)
Figure 151 MEA Antibacterial drugs Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
Figure 152 South Africa Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 153 South Africa Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 154 South Africa Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 155 GCC Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 156 GCC Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 157 GCC Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 158 Rest of MEA Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 159 Rest of MEA Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 160 Rest of MEA Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 161 Global Antibacterial drugs Market: Company Ranking Analysis, 2022
Figure 162 Pfizer: Net Revenue, 2019-2022 (US$ million, AGR%)
Figure 163 Pfizer: Regional Market Shares, 2022
Figure 164 Pfizer: R&D, 2019-2022 (US$ million, AGR%)
Figure 165 Merck: Net Revenue, 2019-2022 (US$ million, AGR%)
Figure 166 Merck: Regional Market Shares, 2022
Figure 167 Merck: R&D, 2019-2022 (US$ million, AGR%)
Figure 168 GSK: Net Revenue, 2019-2022 (US$ million, AGR%)
Figure 169 GSK: Regional Market Shares, 2022
Figure 170 GSK: R&D, 2019-2022 (US$ million, AGR%)
Figure 171 AbbVie: Net Revenue, 2019-2022 (US$ million, AGR%)
Figure 172 AbbVie: Regional Market Shares, 2022
Figure 173 AbbVie: R&D, 2019-2022 (US$ million, AGR%)
Figure 174 Bayer Pharmaceuticals: Net Revenue, 2019-2022 (US$ million, AGR%)
Figure 175 Bayer Pharmaceuticals: Regional Market Shares, 2022
Figure 176 Bayer Pharmaceuticals: R&D, 2019-2022 (US$ million, AGR%)
Figure 177 Janssen Pharma: Net Revenue, 2019-2022 (US$ million, AGR%)
Figure 178 Janssen Pharma: Regional Market Shares, 2022
Figure 179 Janssen Pharma: R&D, 2019-2022 (US$ million, AGR%)
Figure 180 AstraZeneca: Net Revenue, 2019-2022 (US$ million, AGR%)
Figure 181 AstraZeneca: Regional Market Shares, 2022
Figure 182 AstraZeneca: R&D, 2019-2022 (US$ million, AGR%)
Figure 183 Novartis: Net Revenue, 2019-2022 (US$ million)
Figure 184 Novartis: Regional Market Shares, 2022
Figure 185 Novartis: R&D, 2019-2022 (US$ million)
Figure 186 BMS: Net Revenue, 2019-2022 (US$ million)
Figure 187 BMS: Regional Market Shares, 2022
Figure 188 BMS: R&D, 2019-2022 (US$ million)
Figure 189 Sanofi: Net Revenue, 2019-2022 (US$ million)
Figure 190 Sanofi: Regional Market Shares, 2022
Figure 191 Sanofi: R&D, 2019-2022 (US$ million)

　

ページTOPに戻る


　

Summary

Report Details

The Antibacterial drugs Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Difficulties in R&D
Antibacterial drug research and development has been impacted due to limited attractiveness of the market. Major factors that restrict entry of companies are low profit margins for short-course antibacterial treatment as compared to chronic disease drugs, limited marketing lifespan due to emerging resistance, availability of cheap generic drugs, necessary healthcare stewardship to limit antibacterial drug use. Hence, many public–private partnerships have been implemented with government, academia, and the pharmaceutical industry to provide financial and technical support for developing antibacterial drugs. According to WHO, there were only 27 new antibiotics in clinical development against priority pathogens in 2021 as compared 31 in 2017. In the preclinical stage, the number of products has remained constant over the last 3 years. Of the 27 antibiotics in clinical trial stage, only 6 fulfil at least one of WHO’s criteria for innovation. The lack of innovation weakens the effectiveness of the limited number of new antibiotics.

Shortage of antibiotics
According to the US Pharmacopeia Medicine Supply Map Analysis, there is an increased shortage risk for antibiotics, supply chain risks that can lead to antimicrobial resistance. Antibiotics shortage is 42% more likely compared to all other drugs. The analysis is derived from 40 external datasets and proprietary information about the use of USP quality standards, covering 92% of generic medicines approved in the US. Antimicrobial shortage affects addressing the issue of AMR. As per the study, of all types of antibacterial drugs, cephalosporin are at elevated risk for shortage, driven by price. Additionally, 40% of active pharmaceutical ingredients (APIs) used for cephalosporin are currently in shortage. Furthermore, poor-quality medicines drive antimicrobial resistance (AMR) by exposing microorganisms in the body to sub-therapeutic doses of medicines. This leads to patient not receiving enough of the medication’s active pharmaceutical ingredient (API), helping the pathogen to evolve and form more resistant strains can emerge.

Likewise, the European Commission, the Heads of Medicines Agencies (HMA), and the European Medicines Agency (EMA) issued recommendations in July 2023 to prevent shortages of antibiotics (e.g., amoxicillin, amoxicillin/clavulanic acid, penicillin, azithromycin, clarithromycin, ceftriaxone, cefotaxime and piperacillin-tazobactam) crucial in the treatment of respiratory infections. The recommendations were developed by the Executive Steering Group on Shortages and Safety in Medicinal Products (MSSG). EMA and the European Health Emergency Preparedness and Response Authority (HERA) will work with marketing authorization controllers to ensure first and second-line antibiotics for respiratory infections to match demand and avoid shortages.

What Questions Should You Ask before Buying a Market Research Report?
• How is the Antibacterial drugs market evolving?
• What is driving and restraining the Antibacterial drugs market?
• How will each antibacterial drug submarket segment grow during the forecast period and how much revenue will these submarkets account for in 2034?
• How will the market shares for each Antibacterial drugs submarket develop from 2024 to 2034?
• What will be the main driver for the overall market from 2024 to 2034?
• Will leading Antibacterial drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
• Who are the leading players and what are their prospects over the forecast period?
• What are the Antibacterial drugs projects for these leading companies?
• How will the industry evolve during the period between 2024 and 2034? What are the implications of Antibacterial drugs projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the Antibacterial drugs market?
• Where is the Antibacterial drugs market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Antibacterial drugs market today, and over the next 10 years:
• Our 269-pages report provides 113 tables, 192 charts and graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the antibacterial drugs market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Antibacterial drugs prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Drug Class
• Β-lactams
• Quinolones
• Macrolides
• Tetracyclines
• Aminoglycosides
• Sulfonamides
• Phenicols
• Other

Route of Administration
• Enteral
• Parenteral
• Other

Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Rest of Latin America

MEA
• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Antibacterial Drugs Market, 2024 to 2034, with a focus on this segment of these companies’ operations.

Leading companies profiled in the report
• AbbVie Inc.
• AstraZeneca
• Bayer AG
• Bristol-Myers Squibb Company
• GlaxoSmithKline plc
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi

Overall world revenue for Antibacterial drugs Market, 2024 to 2034 in terms of value the market will surpass US$ 39,178.7 million in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Antibacterial drugs Market, 2024 to 2034 report help you?
In summary, our 260-pages report provides you with the following knowledge:

• Revenue forecasts to 2034 for Antibacterial drugs Market, 2024 to 2034 Market, with forecasts for drug class, route of administration and distribution channel each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2034 for five regional and 20 key national markets – See forecasts for the Antibacterial drugs Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles for 10 of the major companies involved in the Antibacterial drugs Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Antibacterial drugs Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.



ページTOPに戻る


Table of Contents

1. Report Overview
1.1 Objectives of the Study
1.2 Introduction to Antibacterial drugs Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered By This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2 Executive Summary
2.1 Geographical Snapshot: Global Antibacterial drugs Market
2.2 Drug Class Segment: Market Attractiveness Index
2.3 Route of Administration Segment: Market Attractiveness Index
2.4 Distribution Channel Segment: Market Attractiveness Index

3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.2 Market Restraining Factors
3.2.3 Market Opportunities
3.2.4 Challenges
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Supplier Power
3.4.2 Buyer Power
3.4.3 Competitive Rivalry
3.4.4 Threat from Substitutes
3.4.5 Threat of New Entrants

4 Global Antibacterial drugs Market Analysis by Drug Class
4.1 Key Findings
4.2 Drug class Segment Growth Prospects
4.3 Global Antibacterial drugs Market Size Estimation and Forecast by Drug Class
4.4 Β-lactams
4.4.1 Β-lactams Market Forecast by Region, 2024-2034 (US$ Mn)
4.4.2 Β-lactams Market Share by Region, 2024-2034 (%)
4.5 Quinolones
4.5.1 Quinolones Market Forecast by Region, 2024-2034 (US$ Mn)
4.5.2 Quinolones Market Share by Region, 2024-2034 (%)
4.6 Macrolides
4.6.1 Macrolides Market Forecast by Region, 2024-2034 (US$ Mn)
4.6.2 Macrolides Market Share by Region, 2024-2034 (%)
4.7 Tetracycline
4.7.1 Tetracycline Market Forecast by Region, 2024-2034 (US$ Mn)
4.7.2 Tetracyclines Market Share by Region, 2024-2034 (%)
4.8 Aminoglycosides
4.8.1 Aminoglycosides Market Forecast by Region, 2024-2034 (US$ Mn)
4.9 Sulfonamides
4.9.1 Sulfonamides Market Forecast by Region, 2024-2034 (US$ Mn)
4.9.2 Sulfonamides Market Share by Region, 2024-2034 (%)
4.10 Phenicols
4.10.1 Phenicols Market Forecast by Region, 2024-2034 (US$ Mn)
4.10.2 Phenicols Market Share by Region, 2024-2034 (%)
4.11 Other
4.11.1 Other Market Forecast by Region, 2024-2034 (US$ Mn)
4.11.2 Other Market Share by Region, 2024-2034 (%)

5 Global Antibacterial drugs Market Analysis by Route of Administration
5.1 Key Findings
5.2 Route of Administration Segment Growth Prospects
5.3 Global Antibacterial drugs Market Size Estimation and Forecast by Route of Administration
5.4 Global Antibacterial drugs Market Share by Route of Administration, 2024 & 2034
5.5 Enteral
5.5.1 Enteral Market Forecast by Region, 2024-2034 (US$ Mn)
5.5.2 Enteral Market Share by Region, 2024-2034 (%)
5.6 Parenteral
5.6.1 Parenteral Market Forecast by Region, 2024-2034 (US$ Mn)
5.6.2 Parenteral Market Share by Region, 2024-2034 (%)
5.7 Other RoA
5.7.1 Other RoA Market Forecast by Region, 2024-2034 (US$ Mn)
5.7.2 Other RoA Market Share by Region, 2024-2034 (%)

6 Global Antibacterial drugs Market Analysis by Distribution Channel
6.1 Key Findings
6.2 Distribution Channel Segment Growth Prospects
6.3 Global Antibacterial drugs Market Size Estimation and Forecast by Distribution Channel
6.4 Global Antibacterial drugs Market Share by Distribution Channel, 2023 & 2033
6.5 Hospital Pharmacies
6.5.1 Hospital Pharmacies Market Forecast by Region, 2024-2034 (US$ Mn)
6.5.2 Hospital Pharmacies Market Share by Region, 2024-2034 (%)
6.6 Retail Pharmacies
6.6.1 Retail Pharmacies Market Forecast by Region, 2024-2034 (US$ Mn)
6.6.2 Retail Pharmacies Market Share by Region, 2024-2034 (%)
6.7 Online Pharmacies
6.7.1 Online Pharmacies Market Forecast by Region, 2024-2034 (US$ Mn)
6.7.2 Online Pharmacies Market Share by Region, 2024-2034 (%)

7 Global Antibacterial drugs Market Analysis by Region
7.1 Key Findings
7.2 Regional Market Size Estimation and Forecast

8 North America Antibacterial drugs Market Analysis
8.1 Key Findings
8.2 North America Antibacterial drugs Market Attractiveness Index
8.3 North America Antibacterial drugs Market by Country, 2024, 2029 & 2034 (US$ Mn)
8.4 North America Antibacterial drugs Market Size Estimation and Forecast by Country
8.5 North America Antibacterial drugs Market Size Estimation and Forecast by Drug Class
8.6 North America Antibacterial drugs Market Size Estimation and Forecast by Route of Administration
8.7 North America Antibacterial drugs Market Size Estimation and Forecast by Distribution Channel
8.8 U.S.
8.8.1 U.S. Antibacterial drugs Market by Drug Class
8.9 Canada
8.9.1 Canada Antibacterial drugs Market by Drug Class

9 Europe Antibacterial drugs Market Analysis
9.1 Key Findings
9.2 Europe Antibacterial drugs Market Attractiveness Index
9.3 Europe Antibacterial drugs Market by Country, 2024, 2029 & 2034 (US$ Mn)
9.4 Europe Antibacterial drugs Market Size Estimation and Forecast by Country
9.5 Europe Antibacterial drugs Market Size Estimation and Forecast by Drug Class
9.6 Europe Antibacterial drugs Market Size Estimation and Forecast by Route of Administration
9.7 Europe Antibacterial drugs Market Size Estimation and Forecast by Distribution Channel
9.8 Germany
9.8.1 Germany Antibacterial drugs Market by Drug Class
9.9 U.K.
9.9.1 U.K. Antibacterial drugs Market by Drug Class
9.10 France
9.10.1 France Antibacterial drugs Market by Drug Class
9.11 Italy
9.11.1 Italy Antibacterial drugs Market by Drug Class
9.12 Spain
9.12.1 Spain Antibacterial drugs Market by Drug Class
9.13 Rest of Europe
9.13.1 Rest of Europe Antibacterial drugs Market by Drug Class

10 Asia Pacific Antibacterial drugs Market Analysis
10.1 Key Findings
10.2 Asia Pacific Antibacterial drugs Market Attractiveness Index
10.3 Asia Pacific Antibacterial drugs Market by Country, 2024, 2029 & 2034 (US$ Mn)
10.4 Asia Pacific Antibacterial drugs Market Size Estimation and Forecast by Country
10.5 Asia Pacific Antibacterial drugs Market Size Estimation and Forecast by Drug Class
10.6 Asia-Pacific Antibacterial drugs Market Size Estimation and Forecast by Route of Administration
10.7 Asia Pacific Antibacterial drugs Market Size Estimation and Forecast by Distribution Channel
10.8 Japan
10.8.1 Japan Antibacterial drugs Market by Drug Class
10.9 China
10.9.1 China Antibacterial drugs Market by Drug Class
10.10 India
10.10.1 India Antibacterial drugs Market by Drug Class
10.11 South Korea
10.11.1 South Korea Antibacterial drugs Market by Drug Class
10.12 Australia
10.12.1 Australia Antibacterial drugs Market by Drug Class
10.13 Rest of APAC
10.13.1 Rest of APAC Antibacterial drugs Market by Drug Class

11 Latin America Antibacterial drugs Market Analysis
11.1 Key Findings
11.2 Latin America Antibacterial drugs Market Attractiveness Index
11.3 Latin America Antibacterial drugs Market by Country, 2024, 2029 & 2034 (US$ Mn)
11.4 Latin America Antibacterial drugs Market Size Estimation and Forecast by Country
11.5 Latin America Antibacterial drugs Market Size Estimation and Forecast by Drug Class
11.6 Latin America Antibacterial drugs Market Size Estimation and Forecast by Route of Administration
11.7 Latin America Antibacterial drugs Market Size Estimation and Forecast by Distribution Channel
11.8 Brazil
11.8.1 Brazil Antibacterial drugs Market by Drug Class
11.9 Mexico
11.9.1 Mexico Antibacterial drugs Market by Drug Class
11.10 Rest of Latin America
11.10.1 Rest of LATAM Antibacterial drugs Market by Drug Class

12 MEA Antibacterial drugs Market Analysis
12.1 Key Findings
12.2 MEA Antibacterial drugs Market Attractiveness Index
12.3 MEA Antibacterial drugs Market by Country, 2024, 2029 & 2034 (US$ Mn)
12.4 MEA Antibacterial drugs Market Size Estimation and Forecast by Country
12.5 MEA Antibacterial drugs Market Size Estimation and Forecast by Drug Class
12.6 MEA Antibacterial drugs Market Size Estimation and Forecast by Route of Administration
12.7 MEA Antibacterial drugs Market Size Estimation and Forecast by Distribution Channel
12.8 South Africa
12.8.1 South Africa Antibacterial drugs Market by Drug Class
12.9 GCC
12.9.1 GCC Antibacterial drugs Market by Drug Class
12.10 Rest of MEA
12.10.1 Rest of MEA Antibacterial drugs Market by Drug Class

13 Competitive Landscape
13.1 Company Ranking Analysis
13.2 Key Business Strategy Analysis


14 Company Profiles
14.1 Pfizer
14.1.1 Company Snapshot
14.1.2 Company Overview
14.1.3 Financial Analysis
14.1.4 Product Benchmarking
14.1.5 Strategic Outlook
14.2 Merck
14.2.1 Company Snapshot
14.2.2 Company Overview
14.2.3 Financial Analysis
14.2.4 Product Benchmarking
14.2.5 Strategic Outlook
14.3 GSK
14.3.1 Company Snapshot
14.3.2 Company Overview
14.3.3 Financial Analysis
14.3.4 Product Benchmarking
14.3.5 Strategic Outlook
14.4 AbbVie
14.4.1 Company Snapshot
14.4.2 Company Overview
14.4.3 Financial Analysis
14.4.4 Product Benchmarking
14.4.5 Strategic Outlook
14.5 Bayer Pharmaceuticals
14.5.1 Company Snapshot
14.5.2 Company Overview
14.5.3 Financial Analysis
14.5.4 Product Benchmarking
14.5.5 Strategic Outlook
14.6 Janssen Pharma (subsidiary of Johnson and Johnson)
14.6.1 Company Snapshot
14.6.2 Company Overview
14.6.3 Financial Analysis
14.6.4 Product Benchmarking
14.6.5 Strategic Outlook
14.7 AstraZeneca
14.7.1 Company Snapshot
14.7.2 Company Overview
14.7.3 Financial Analysis
14.7.4 Product Benchmarking
14.7.5 Strategic Outlook
14.8 Novartis
14.8.1 Company Snapshot
14.8.2 Company Overview
14.8.3 Financial Analysis
14.8.4 Product Benchmarking
14.8.5 Strategic Outlook
14.9 Bristol-Myers Squibb Company
14.9.1 Company Snapshot
14.9.2 Company Overview
14.9.3 Financial Analysis
14.9.4 Product Benchmarking
14.9.5 Strategic Outlook
14.10 Sanofi
14.10.1 Company Snapshot
14.10.2 Company Overview
14.10.3 Financial Analysis
14.10.4 Product Benchmarking
14.10.5 Strategic Outlook

15 Conclusion and Recommendations
15.1 Final findings of report
15.2 Recommendations for Market Players

ページTOPに戻る



List of Tables/Graphs

List of Tables
Table 1 Global Antibacterial drugs Market Snapshot, 2024 & 2034 (US$ million, CAGR %)
Table 2 Antibacterial drugs Market, By Region, 2022-2034 (USD Mn, AGR %, CAGR %) (V-shaped Recovery)
Table 3 Gynecology Drugs Market, By Region, 2024-2034 (US$ Mn, AGR %, CAGR %) (U-shaped Recovery)
Table 4 Antibacterial drugs Market, By Region, 2024-2034 (US$ Mn, AGR %, CAGR %) (W-shaped Recovery)
Table 5 Antibacterial drugs Market, By Region, 2022-2034 (US$ Mn, AGR %, CAGR %) (L-shaped Recovery)
Table 6 Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 7 Examples of Beta-Lactam treatments
Table 8 β-lactams Market, by Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 9 Quinolones Market, by Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 10 Macrolides Market, by Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 11 Tetracyclines Market, by Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 12 Aminoglycosides Market, by Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 13 Sulfonamides Market, by Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 14 Phenicols Market, by Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 15 Others Market, by Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 16 Route of Administration Market, By Type 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 17 Examples of Enteral route drugs
Table 18 Enteral Market, by Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 19 Parenteral Market, by Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 20 Other Market, by Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 21 Antibacterial drugs Distribution Channel Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 22 Hospital Pharmacies Market, by Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 23 Retail Pharmacies Market, by Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 24 Online Pharmacies Market, by Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 25 Antibacterial drugs Market, By Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 26 North America Antibacterial drugs Market, By Country, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 27 North America Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 28 North America Route of administration Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 29 North America Distribution Channel Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 30 US Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 31 US Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 32 Canada Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 33 Canada Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 34 Europe Antibacterial drugs Market, By Country, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 35 Europe Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 36 Europe Route of administration Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 37 Europe Distribution Channel Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 38 Germany Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 39 Germany Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 40 UK Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 41 UK Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 42 France Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 43 France Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 44 Italy Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 45 Italy Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 46 Spain Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 47 Spain Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 48 Rest of Europe Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 49 Rest of Europe Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 50 Asia Pacific Antibacterial drugs Market, By Country, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 51 Asia Pacific Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 52 Asia-Pacific Route of Administration Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 53 Asia-Pacific Distribution Channel Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 54 Japan Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 55 Japan Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 56 China Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 57 China Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 58 India Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 59 India Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 60 South Korea Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 61 South Korea Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 62 Australia Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 63 Australia Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 64 Rest of Asia Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 65 Rest of Asia Pacific Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 66 Latin America Antibacterial drugs Market, By Country, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 67 Latin America Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 68 Latin America Route of Administration Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 69 Latin America Distribution Channel Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 70 Brazil Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 71 Brazil Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 72 Mexico Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 73 Mexico Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 74 Rest of Latin America Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 75 Rest of LATAM Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 76 MEA Antibacterial drugs Market, By Country, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 77 MEA Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 78 MEA Route of Administration Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 79 MEA Distribution Channel Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 80 South Africa Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 81 South Africa Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 82 GCC Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 83 GCC Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 84 Rest of MEA Antibacterial drugs Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 85 Rest of MEA Antibacterial Drug Class Market, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Table 86 Key Business Strategies Adopted by Key Players in Global Antibacterial drugs Market Details
Table 87 Pfizer: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 88 Pfizer: Product Benchmarking
Table 89 Pfizer Inc: Company Recent Developments
Table 90 Merck: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 91 Merck: Product Benchmarking
Table 92 Merck: Company Recent Developments
Table 93 GSK: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 94 GSK: Product Benchmarking
Table 95 GlaxoSmithKline: Company Recent Developments
Table 96 AbbVie: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website)
Table 97 AbbVie: Product Benchmarking
Table 98 AbbVie Inc: Company Recent Developments
Table 99 Bayer Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 100 Bayer Pharmaceuticals: Product Benchmarking
Table 101 Bayer Pharmaceuticals: Company Recent Developments
Table 102 Janssen Pharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 103 Janssen Pharma: Product Benchmarking
Table 104 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 105 AstraZeneca: Product Benchmarking
Table 106 AstraZeneca: Strategic Outlook
Table 107 Novartis: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 108 Novartis: Product Benchmarking
Table 109 AstraZeneca: Strategic Outlook
Table 110 BMS: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 111 BMS: Product Benchmarking
Table 112 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 113 Sanofi: Product Benchmarking
 
List of Figures
Figure 1 Global Antibacterial drugs Market Segmentation
Figure 2 Global Antibacterial drugs Market Forecast by Region: Market Attractiveness Index
Figure 3 Global Antibacterial drugs Market by Drug Class: Market Attractiveness Index
Figure 4 Global Antibacterial drugs Market by Route of Administration: Market Attractiveness Index
Figure 5 Global Antibacterial drugs Market by Distribution Channel: Market Attractiveness Index
Figure 6 Global Antibacterial drugs Market: Market Dynamics
Figure 7 Global Antibacterial drugs Market by Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%)): “V” Shaped Recovery
Figure 8 Global Antibacterial drugs Market by Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%)): “U” Shaped Recovery
Figure 9 Global Antibacterial drugs Market by Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%)): “W” Shaped Recovery
Figure 10 Global Antibacterial drugs Market by Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%)): “L” Shaped Recovery
Figure 11 Global Antibacterial drugs Market: Porter’s Five Forces Analysis
Figure 12 Global Antibacterial drugs Market Forecast by Drug Class 2023 (Revenue, CAGR%)
Figure 13 Global Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 14 Global Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 15 Β-lactams Market Forecast by Region, 2024-2034 (US$ million)
Figure 16 Β-lactams Market Share Forecast by Region, 2024-2034 (%)
Figure 17 Quinolones Market Forecast by Region, 2024-2034 (US$ million)
Figure 18 Quinolones Market Share Forecast by Region, 2024-2034 (%)
Figure 19 Macrolides Market Forecast by Region, 2024-2034 (US$ million)
Figure 20 Macrolides Market Share Forecast by Region, 2024-2034 (%)
Figure 21 Tetracycline Market Forecast by Region, 2024-2034 (US$ million)
Figure 22 Tetracyclines Market Share Forecast by Region, 2024-2034 (%)
Figure 23 Aminoglycosides Market Forecast by Region, 2024-2034 (US$ million)
Figure 24 Sulfonamides Market Forecast by Region, 2024-2034 (US$ million)
Figure 25 Sulfonamides Market Share Forecast by Region, 2024-2034 (%)
Figure 26 Phenicols Market Forecast by Region, 2024-2034 (US$ million)
Figure 27 Phenicols Market Share Forecast by Region, 2024-2034 (%)
Figure 28 Other Disease Market Forecast by Region, 2024-2034 (US$ million)
Figure 29 Other Market Share Forecast by Region, 2024-2034 (%)
Figure 30 Global Antibacterial drugs Market Forecast by Route of Administration 2023 (Revenue, CAGR%)
Figure 31 Global Antibacterial drugs Market Forecast by Route of Administration, 2024-2034 (US$ million, AGR %)
Figure 32 Global Antibacterial drugs Market Share Forecast by Route of Administration, 2024, 2029, 2034 (%)
Figure 33 Enteral Market Forecast by Region, 2024-2034 (US$ million)
Figure 34 Enteral Market Share Forecast by Region, 2024-2034 (%)
Figure 35 Parenteral Market Forecast by Region, 2024-2034 (US$ million)
Figure 36 Parenteral Market Share Forecast by Region, 2024-2034 (%)
Figure 37 Other Market Forecast by Region, 2024-2034 (US$ million)
Figure 38 Other Market Share Forecast by Region, 2024-2034 (%)
Figure 39 Global Antibacterial drugs Market Forecast by Distribution Channel 2023 (Revenue, CAGR%)
Figure 40 Global Antibacterial drugs Market Forecast by Distribution Channel, 2024-2034 (US$ million, AGR %)
Figure 41 Global Antibacterial drugs Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
Figure 42 Hospital Pharmacies Market Forecast by Region, 2024-2034 (US$ million)
Figure 43 Hospital Pharmacies Market Share Forecast by Region, 2024-2034 (%)
Figure 44 Retail Pharmacies Market Forecast by Region, 2024-2034 (US$ million)
Figure 45 Retail Pharmacies Market Share Forecast by Region, 2024-2034 (%)
Figure 46 Online Pharmacies Market Forecast by Region, 2024-2034 (US$ million)
Figure 47 Online Pharmacies Market Share Forecast by Region, 2024-2034 (%)
Figure 48 Global Antibacterial drugs Market Forecast by Region 2024, 2029, 2034 (Revenue)
Figure 49 Global Antibacterial drugs Market Share Forecast by Region 2024, 2029, 2034 (%)
Figure 50 Global Antibacterial drugs Market by Region, 2024-2034 (US$ Mn, AGR (%), CAGR (%))
Figure 51 North America Antibacterial drugs Market Attractiveness Index, 2023
Figure 52 North America Antibacterial drugs Market by Region, 2024, 2029 & 2034 (US$ million)
Figure 53 North America Antibacterial drugs Market Forecast by Country, 2024-2034 (US$ million, AGR %)
Figure 54 North America Antibacterial drugs Market Share Forecast by Country, 2024, 2029, 2034(%)
Figure 55 North America Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 56 North America Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 57 North America Antibacterial drugs Market Forecast by Route of Administration, 2024-2034 (US$ million, AGR %)
Figure 58 North America Antibacterial drugs Market Share Forecast by Route of Administration, 2024, 2029, 2034 (%)
Figure 59 North America Antibacterial drugs Market Forecast by Distribution Channel, 2024-2034 (US$ million, AGR %)
Figure 60 North America Antibacterial drugs Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
Figure 61 U.S. Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 62 U.S. Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 63 U.S. Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 64 Canada Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 65 Canada Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 66 Canada Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 67 Europe Antibacterial drugs Market Attractiveness Index, 2023
Figure 68 Europe Antibacterial drugs Market by Region, 2024, 2029 & 2034 (US$ million)
Figure 69 Europe Antibacterial drugs Market Forecast by Country, 2024-2034 (US$ million, AGR %)
Figure 70 Europe Antibacterial drugs Market Share Forecast by Country, 2024, 2029, 2034 (%)
Figure 71 Europe Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 72 Europe Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 73 Europe Antibacterial drugs Market Forecast by Route of Administration, 2024-2034 (US$ million, AGR %)
Figure 74 Europe Antibacterial drugs Market Share Forecast by Route of Administration, 2024, 2029, 2034 (%)
Figure 75 Europe Antibacterial drugs Market Forecast by Distribution Channel, 2024-2034 (US$ million, AGR %)
Figure 76 Europe Antibacterial drugs Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
Figure 77 Germany Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 78 Germany Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 79 Germany Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 80 UK Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 81 U.K. Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 82 U.K. Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 83 France Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 84 France Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 85 France Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 86 Italy Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 87 Italy Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 88 Italy Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 89 Spain Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 90 Spain Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 91 Spain Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 92 Rest of Europe Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 93 Rest of Europe Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 94 Rest of Europe Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 95 Asia Pacific Antibacterial drugs Market Attractiveness Index, 2023
Figure 96 Asia Pacific Antibacterial drugs Market by Region, 2024, 2029 & 2034 (US$ million)
Figure 97 Asia Pacific Antibacterial drugs Market Forecast by Country, 2024-2034 (US$ million, AGR %)
Figure 98 Asia Pacific Antibacterial drugs Market Share Forecast by Country, 2024, 2029, 2034 (%)
Figure 99 Asia Pacific Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 100 Asia Pacific Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 101 Asia-Pacific Antibacterial drugs Market Forecast by Route of Administration, 2024-2034 (US$ million, AGR %)
Figure 102 Asia-Pacific Antibacterial drugs Market Share Forecast by Route of Administration, 2024, 2029, 2034 (%)
Figure 103 Asia Pacific Antibacterial drugs Market Forecast by Distribution Channel, 2024-2034 (US$ million, AGR %)
Figure 104 Asia Pacific Antibacterial drugs Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
Figure 105 Japan Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 106 Japan Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 107 Japan Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 108 China Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 109 China Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 110 China Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 111 India Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 112 India Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 113 India Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 114 South Korea Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 115 South Korea Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 116 South Korea Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 117 Australia Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 118 Australia Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 119 Australia Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 120 Rest of Asia Pacific Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 121 Rest of APAC Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 122 Rest of APAC Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 123 Latin America Antibacterial drugs Market Attractiveness Index, 2023
Figure 124 Latin America Antibacterial drugs Market by Region, 2024, 2029 & 2034 (US$ million)
Figure 125 Latin America Antibacterial drugs Market Forecast by Country, 2024-2034 (US$ million, AGR %)
Figure 126 Latin America Antibacterial drugs Market Share Forecast by Country, 2024, 2029, 2034 (%)
Figure 127 Latin America Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 128 Latin America Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 129 Latin America Antibacterial drugs Market Forecast by Route of Administration, 2024-2034 (US$ million, AGR %)
Figure 130 Latin America Antibacterial drugs Market Share Forecast by Route of Administration, 2024, 2029, 2034 (%)
Figure 131 Latin America Antibacterial drugs Market Forecast by Distribution Channel, 2024-2034 (US$ million, AGR %)
Figure 132 Latin America Antibacterial drugs Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
Figure 133 Brazil Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 134 Brazil Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 135 Brazil Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 136 Mexico Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 137 Mexico Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 138 Mexico Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 139 Rest of LATAM Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 140 Rest of LATAM Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 141 Rest of LATAM Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 142 MEA Antibacterial drugs Market Attractiveness Index, 2023
Figure 143 MEA Antibacterial drugs Market by Region, 2024, 2029 & 2034 (US$ million)
Figure 144 MEA Antibacterial drugs Market Forecast by Country, 2024-2034 (US$ million, AGR %)
Figure 145 MEA Antibacterial drugs Market Share Forecast by Country, 2024, 2029, 2034 (%)
Figure 146 MEA Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 147 MEA Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 148 MEA Antibacterial drugs Market Forecast by Route of Administration, 2024-2034 (US$ million, AGR %)
Figure 149 MEA Antibacterial drugs Market Share Forecast by Route of Administration, 2024, 2029, 2034 (%)
Figure 150 MEA Antibacterial drugs Market Forecast by Distribution Channel, 2024-2034 (US$ million, AGR %)
Figure 151 MEA Antibacterial drugs Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
Figure 152 South Africa Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 153 South Africa Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 154 South Africa Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 155 GCC Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 156 GCC Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 157 GCC Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 158 Rest of MEA Antibacterial drugs Market Forecast, 2024-2034 (US$ million, AGR %)
Figure 159 Rest of MEA Antibacterial drugs Market Forecast by Drug Class, 2024-2034 (US$ million, AGR %)
Figure 160 Rest of MEA Antibacterial drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 161 Global Antibacterial drugs Market: Company Ranking Analysis, 2022
Figure 162 Pfizer: Net Revenue, 2019-2022 (US$ million, AGR%)
Figure 163 Pfizer: Regional Market Shares, 2022
Figure 164 Pfizer: R&D, 2019-2022 (US$ million, AGR%)
Figure 165 Merck: Net Revenue, 2019-2022 (US$ million, AGR%)
Figure 166 Merck: Regional Market Shares, 2022
Figure 167 Merck: R&D, 2019-2022 (US$ million, AGR%)
Figure 168 GSK: Net Revenue, 2019-2022 (US$ million, AGR%)
Figure 169 GSK: Regional Market Shares, 2022
Figure 170 GSK: R&D, 2019-2022 (US$ million, AGR%)
Figure 171 AbbVie: Net Revenue, 2019-2022 (US$ million, AGR%)
Figure 172 AbbVie: Regional Market Shares, 2022
Figure 173 AbbVie: R&D, 2019-2022 (US$ million, AGR%)
Figure 174 Bayer Pharmaceuticals: Net Revenue, 2019-2022 (US$ million, AGR%)
Figure 175 Bayer Pharmaceuticals: Regional Market Shares, 2022
Figure 176 Bayer Pharmaceuticals: R&D, 2019-2022 (US$ million, AGR%)
Figure 177 Janssen Pharma: Net Revenue, 2019-2022 (US$ million, AGR%)
Figure 178 Janssen Pharma: Regional Market Shares, 2022
Figure 179 Janssen Pharma: R&D, 2019-2022 (US$ million, AGR%)
Figure 180 AstraZeneca: Net Revenue, 2019-2022 (US$ million, AGR%)
Figure 181 AstraZeneca: Regional Market Shares, 2022
Figure 182 AstraZeneca: R&D, 2019-2022 (US$ million, AGR%)
Figure 183 Novartis: Net Revenue, 2019-2022 (US$ million)
Figure 184 Novartis: Regional Market Shares, 2022
Figure 185 Novartis: R&D, 2019-2022 (US$ million)
Figure 186 BMS: Net Revenue, 2019-2022 (US$ million)
Figure 187 BMS: Regional Market Shares, 2022
Figure 188 BMS: R&D, 2019-2022 (US$ million)
Figure 189 Sanofi: Net Revenue, 2019-2022 (US$ million)
Figure 190 Sanofi: Regional Market Shares, 2022
Figure 191 Sanofi: R&D, 2019-2022 (US$ million)

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（抗感染性薬物）の最新刊レポート

Visiongain社の医薬・化学品分野での最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


Visiongain社はどのような調査会社ですか?


英国の調査会社ヴィジョンゲイン社（Visiongain）は、通信とエネルギーのほか、自動車や化学・医薬品、金属など、広範な市場を対象に調査を行っています。自動車市場については、市場全般に関する調査のほ... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/12/30　10:26

159.18 円

166.42 円

203.02 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.